Economic information and modeling report
Modeling overview
2 evidence topics · 1 source
Summary
The report contains projected annual U.S. sales of $5 million, $56 million, $227 million, $435 million, and $685 million for 2026 through 2030, respectively. This sales forecast is not a relutrigine budget-impact model and does not provide a payer-specific eligible population, treatment acquisition cost, or incremental budget result.
Relutrigine-specific health technology assessments and systematic reviews
No evidence found.